JAZZ · XBRL financial data

Jazz Pharmaceuticals financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (JAZZ's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	2,364	3,094	3,659	3,834	4,069	4,268
Selling, general and administrative	854	1,452	1,417	1,343	1,385	1,809
Operating income (loss)	378	170	(66)	579	717	(430)
Interest income	11	2	12	65	106	86
Interest expense	76	90	33	33	—	—
Income tax expense (benefit)	34	216	(159)	(120)	(91)	(272)
Net income (loss)	239	(330)	(224)	415	560	(356)
Earnings per share, basic USD per share	4.28	(5.52)	(3.58)	6.55	9.06	(5.84)
Earnings per share, diluted USD per share	4.22	(5.52)	(3.58)	6.10	8.65	(5.84)
Weighted average shares, basic millions of shares	56	60	63	63	62	61
Weighted average shares, diluted millions of shares	57	60	63	72	66	61

Fiscal years (JAZZ's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	1,058	591	881	1,506	2,413	1,392
Accounts receivable	396	563	651	706	717	831
Inventory	95	1,073	714	597	480	417
Total current assets	2,840	2,611	2,606	3,435	4,629	4,166
Property and equipment, net	128	—	—	—	—	—
Right-of-use asset	129	87	73	65	54	59
Goodwill	958	1,828	1,693	1,753	1,716	1,829
Total assets	6,536	12,299	10,835	11,393	12,012	11,659
Accounts payable	27	100	91	103	78	122
Accrued liabilities	353	666	803	794	911	1,034
Current portion of long-term debt	246	31	31	605	31	1,030
Total current liabilities	654	809	933	1,537	1,039	2,243
Long-term debt	1,849	6,019	5,693	5,108	6,078	4,328
Lease liability, non-current	140	87	72	59	39	51
Retained earnings	1,160	830	734	879	1,127	646
Total stockholders' equity	3,660	3,965	3,086	3,737	4,094	4,319
Total liabilities and equity	6,536	12,299	10,835	11,393	12,012	11,659
Common shares outstanding (cover page) millions of shares	56	62	63	62	61	62

Fiscal years (JAZZ's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	239	(330)	(224)	415	560	(356)
Stock-based compensation	121	189	222	227	248	291
Depreciation and amortization	19	27	30	30	33	42
Net cash from operating activities	900	779	1,272	1,092	1,396	1,356
Purchases of property and equipment	15	28	29	24	38	59
Net cash from investing activities	(1,008)	(5,212)	(446)	(163)	(508)	(1,510)
Share repurchases	147	0	0	270	311	125
Net cash from financing activities	528	3,971	(529)	(305)	21	(873)
Net change in cash	420	(466)	290	625	907	(1,021)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Jazz Pharmaceuticals	2,036	1,243	506*	64.2M	—	Q3 FY26 10-QSep 30, 2026
Corcept Therapeutics	99	340	143*	109.4M	—	Q3 FY26 10-QSep 30, 2026
Repligen	727	209	43*	63.9M	—	Q3 FY26 10-QSep 30, 2026
Biomarin Pharmaceutical	736	1,025	188*	193.7M	—	Q3 FY26 10-QSep 30, 2026
Revolution Medicines	815	not reported	(387)*	214.3M	10.2 quarters	Q2 FY26 10-QJun 30, 2026
Madrigal Pharmaceuticals	515	431	121*	23.2M	—	Q3 FY26 10-QSep 30, 2026
Ionis Pharmaceuticals	350	268	566*	166.2M	—	Q2 FY26 10-QJun 30, 2026
Alkermes	631	480	93*	168.0M	—	Q3 FY26 10-QSep 30, 2026
Halozyme Therapeutics	163	481	241*	113.5M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.